Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

The Food and Drug Administration (FDA) last week granted the first approval for UK pharma major AstraZeneca’s Datroway ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.